United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca

BioNTech SE

Moderna

The ability to globally distribute a vaccine is as important as the vaccine itself. To the best-equipped victors go the spoils.

What If More Than One Company Wins the Coronavirus Vaccine Race?

Shopify

Zoom Video

The momentum is not yet over for these three promising companies that are doing their part in combating the COVID-19 pandemic.

3 Best Coronavirus Stocks to Watch in September

CureVac B.V

Inovio Pharmaceuticals

Johnson & Johnson

Novavax

Here are the answers to your top questions about where things stand with the development of COVID-19 vaccines.

Coronavirus Vaccine Race: 7 Key Things You'll Want to Know

The companies, which are developing the vaccine together, said in a statement that the trial is proceeding as planned and they expect to have enrolled 30,000 participants by next week. 

Pfizer proposes expansion of late-stage coronavirus vaccine trial

AbbVie

Amgen

Gilead Sciences

GlaxoSmithKline

Merck

Novartis

Roche Holding AG

Sanofi

As evidence grew this spring that the drug remdesivir was helping COVID-19 patients, some Wall Street investors bet on analysts’ estimates that its maker, Gilead Sciences Inc , could charge up to $10,000 for the treatment.

Big Pharma wages stealth war on drug price watchdog

Eli Lilly

Pfizer’s stock has gained 28% since the March 23 lows of this year, in-line with Eli Lilly & Company stock, which has gained 29% of its value. The lockdown in various parts of the world has had a negative impact on the pharmaceuticals industry worldwide due to deferment of elective surgeries.

Eli Lilly Stock A Better Bet Compared To Pfizer

Pfizer (PFE) and BioNTech are in discussion with the European Commission to supply potentially 200 million doses of their COVID-19 vaccine BNT162b2 on approval.

Pfizer, BioNTech May Supply 200M Coronavirus Vaccine Doses in EU

Abbott Labs

According to the GuruFocus All-in-One Screener as of Sep. 10, the following healthcare stocks are popular among gurus.

5 Health Care Stocks in Gurus' Portfolios

The pause in AstraZeneca's (AZN) voluntary coronavirus study following an adverse event provides its competitors a breather.

Pausing of AstraZeneca's Coronavirus Study Aids Pfizer, Moderna

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that more than 50 abstracts representing data from nine approved and investigational Pfizer medicines, including several biomarker-driven and immuno-therapies, will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 being held from September 19-21, 2020.

Pfizer to Present Latest Scientific Advancements from Its Industry-Leading Portfolio at the ESMO Virtual Congress 2020

The big drugmaker is taking a quiet but smart step with its COVID-19 vaccine program.

Pfizer's Latest Stealthy Move Could Help It Win the Coronavirus Vaccine Race

The duo is in contract negotiations with the European Commission.

Pfizer and BioNTech to Potentially Sell 300 Million Doses of Its Coronavirus Vaccine to EU

Trillium Therapeutics

Shares of clinical stage immuno-oncology company Trillium Therapeutics Inc's (NASDAQ: TRIL) are trading higher on encouraging updated data from its ongoing lead cancer candidates TTI-622 and TTI-621 that was released after hours Tuesday.

Trillium Therapeutics Up 40% On Data From Lead Cancer Candidates, Pfizer Investment

The COVID-19 vaccine developers pledge to observe high ethical standards and sound scientific principles in conducting clinical studies and manufacturing of vaccines.

CEOs of Nine Coronavirus Vaccine Makers Sign Safety Pledge

BioNTech and Pfizer announced both positive early immunization data and a nearly complete supply deal for their Covid vaccine candidate, sparking shares of both BNTX stock and PFE stock.
The post Pfizer, BioNTech Ink Covid Vaccine Deal With EU, Post Positive Trial Data appeared first on Investor's Business Daily.

Pfizer, BioNTech Ink Covid Vaccine Deal With EU, Post Positive Trial Data

Shares of Pfizer Inc. (NYSE: PFE) and its coronavirus vaccine development partner BioNTech SE – ADR (NASDAQ: BNTX) are advancing Wednesday thanks to multiple catalysts.

Pfizer, BioNTech Rally On A Trio Of Catalysts

BioNTech BNTX, +2.15% and Pfizer Inc. PFE, -1.18% , which are developing a COVID-19 vaccine candidate, said in a news release on Wednesday that they plan to pursue regulatory review for BNT162b2 in October, depending on the success of the vaccine in late-stage clinical trials.

BioNTech, Pfizer expect clinical 'answer' on coronavirus vaccine in late October

Pfizer could very likely be the first company to secure emergency use authorization for its coronavirus vaccine candidate.

Is Pfizer the Best Way to Play the Coronavirus Vaccine Race?

Shares of several companies that are developing COVID-19 vaccines rallied on Wednesday morning before the market opened following a Stat News report published Tuesday that said AstraZeneca AZN, +2.10% [ AZN, -1.62% halted a Phase 3 clinical trial for its coronavirus vaccine candidate over safety concerns.

Moderna, BioNTech, Pfizer stocks rally after AstraZeneca COVID-19 vaccine trial is reportedly halted

NEW YORK and MAINZ, Germany, Sept.  09, 2020  (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced preliminary preclinical data in mouse and non-human primate models from their BNT162b2 mRNA-based vaccine program against SARS-CoV-2, the virus that causes COVID-19 disease. In a non-human primate preclinical study, immunization with BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate, protected rhesus macaques against SARS-CoV-2 infection. The manuscript describing these preclinical data is available on the preprint server bioRxiv and is concurrently undergoing scientific peer-review for potential publication.

Pfizer and BioNTech Announce Data From Preclinical Studies of mRNA-Based Vaccine Candidate Against COVID-19

Shares of BioNTech SE BNTX, +2.15% rallied 5.0% in premarket trading Wednesday, and Pfizer Inc.

Pfizer, BioNTech conclude talks over supplying EU with SARS-CoV-2 vaccine candidate

NEW YORK and MAINZ, Germany, Sept.  09, 2020  (GLOBE NEWSWIRE) --  Pfizer  (NYSE: PFE) and  BioNTech SE  (Nasdaq: BNTX) today announced that they had concluded exploratory talks with the European Commission for a proposed supply of 200 million doses of their investigational BNT162 mRNA-based vaccine candidate against SARS-CoV-2 to European Union (EU) Member States, with an option for further 100 million doses. Deliveries would be starting by the end of 2020, subject to clinical success and regulatory authorization. The companies will now enter into contract negotiations with the European Commission. 

Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2

Medical experts fear a vaccine approval could be politically motivated as the federal government pushes states to have vaccine distribution sites ready by Nov.1, two days before the U.S. presidential election.

Pfizer CEO says people who don't take the coronavirus vaccine will become 'weak link' that allows it to spread

Nine leading U.S. and European vaccine developers pledged to uphold the scientific standards that their experimental immunizations will be held against, amid a hurried global race to contain the pandemic.

Nine biopharma CEOs pledge to make safety the main focus in coronavirus vaccine development

The vaccine developers are likely to pledge to observe high ethical standards in conducting clinical studies and manufacturing of the vaccines, the Wall Street report said.

News for Pfizer Stock (PFE)